 Pamela Zeitlin
Concepts (482)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis Transmembrane Conductance Regulator | 45 | 2022 | 316 | 7.160 |
Why?
| | Cystic Fibrosis | 68 | 2022 | 1061 | 6.250 |
Why?
| | Chlorides | 11 | 2020 | 138 | 1.570 |
Why?
| | Chloride Channels | 12 | 2013 | 38 | 1.560 |
Why?
| | Benzodioxoles | 6 | 2022 | 102 | 1.220 |
Why?
| | Bronchi | 9 | 2012 | 253 | 1.090 |
Why?
| | Epithelial Cells | 13 | 2024 | 1060 | 1.080 |
Why?
| | Mutation | 18 | 2022 | 3674 | 1.040 |
Why?
| | Nasal Mucosa | 11 | 2024 | 108 | 0.970 |
Why?
| | Interleukin-8 | 8 | 2017 | 262 | 0.860 |
Why?
| | Phenylbutyrates | 5 | 2006 | 22 | 0.800 |
Why?
| | Indoles | 3 | 2022 | 379 | 0.760 |
Why?
| | Alprostadil | 2 | 2013 | 32 | 0.720 |
Why?
| | Aminophenols | 6 | 2022 | 141 | 0.670 |
Why?
| | Respiratory Mucosa | 8 | 2024 | 313 | 0.670 |
Why?
| | Endoplasmic Reticulum | 9 | 2014 | 256 | 0.600 |
Why?
| | Dependovirus | 5 | 2007 | 58 | 0.590 |
Why?
| | Genetic Therapy | 8 | 2011 | 295 | 0.580 |
Why?
| | Pseudomonas Infections | 5 | 2020 | 217 | 0.560 |
Why?
| | Digitoxin | 1 | 2017 | 3 | 0.560 |
Why?
| | Epithelium | 5 | 2021 | 313 | 0.540 |
Why?
| | Ubiquitin | 2 | 2014 | 62 | 0.540 |
Why?
| | Protein Processing, Post-Translational | 3 | 2014 | 448 | 0.520 |
Why?
| | Lung | 11 | 2022 | 3928 | 0.520 |
Why?
| | Proteomics | 3 | 2012 | 988 | 0.510 |
Why?
| | Mucociliary Clearance | 3 | 2021 | 43 | 0.500 |
Why?
| | Proteasome Endopeptidase Complex | 3 | 2014 | 145 | 0.490 |
Why?
| | Sputum | 10 | 2020 | 309 | 0.480 |
Why?
| | Sp1 Transcription Factor | 2 | 2006 | 25 | 0.470 |
Why?
| | Anti-Inflammatory Agents | 2 | 2017 | 471 | 0.470 |
Why?
| | Ion Transport | 5 | 2020 | 58 | 0.420 |
Why?
| | Scorpion Venoms | 1 | 2013 | 2 | 0.420 |
Why?
| | Gene Expression Regulation | 7 | 2009 | 2522 | 0.400 |
Why?
| | Cell Line | 11 | 2014 | 2768 | 0.400 |
Why?
| | Protein Array Analysis | 2 | 2012 | 56 | 0.400 |
Why?
| | Pseudomonas aeruginosa | 4 | 2016 | 343 | 0.390 |
Why?
| | Lysine | 1 | 2014 | 266 | 0.390 |
Why?
| | Humans | 80 | 2024 | 129705 | 0.380 |
Why?
| | Lubiprostone | 3 | 2022 | 9 | 0.380 |
Why?
| | Inflammation | 3 | 2017 | 2705 | 0.350 |
Why?
| | NF-kappa B | 4 | 2009 | 687 | 0.350 |
Why?
| | Respiratory System | 3 | 2022 | 153 | 0.340 |
Why?
| | Quinolones | 4 | 2022 | 123 | 0.340 |
Why?
| | Trachea | 3 | 2008 | 233 | 0.340 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2010 | 42 | 0.330 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2006 | 819 | 0.330 |
Why?
| | Caveolin 1 | 1 | 2009 | 20 | 0.330 |
Why?
| | Aspergillus fumigatus | 1 | 2008 | 20 | 0.310 |
Why?
| | Estrogen Antagonists | 1 | 2008 | 46 | 0.310 |
Why?
| | Endocytosis | 1 | 2009 | 162 | 0.300 |
Why?
| | Dinoprostone | 3 | 2022 | 188 | 0.300 |
Why?
| | Proteome | 4 | 2009 | 426 | 0.300 |
Why?
| | Protein Folding | 4 | 2004 | 261 | 0.300 |
Why?
| | Tamoxifen | 1 | 2008 | 199 | 0.290 |
Why?
| | Calcium | 3 | 2008 | 1182 | 0.290 |
Why?
| | Transcription Factor CHOP | 1 | 2007 | 29 | 0.280 |
Why?
| | Ofloxacin | 1 | 2007 | 26 | 0.280 |
Why?
| | Levofloxacin | 1 | 2007 | 28 | 0.280 |
Why?
| | Drugs, Investigational | 1 | 2007 | 32 | 0.270 |
Why?
| | Adolescent | 31 | 2020 | 20355 | 0.270 |
Why?
| | S-Nitrosoglutathione | 1 | 2006 | 7 | 0.270 |
Why?
| | Mutant Proteins | 1 | 2007 | 97 | 0.270 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2006 | 21 | 0.260 |
Why?
| | Adult | 34 | 2022 | 35595 | 0.260 |
Why?
| | Nebulizers and Vaporizers | 2 | 2005 | 82 | 0.260 |
Why?
| | Interleukin-13 | 2 | 2024 | 147 | 0.260 |
Why?
| | Membrane Potentials | 5 | 2013 | 260 | 0.250 |
Why?
| | Pneumonia, Bacterial | 1 | 2007 | 112 | 0.250 |
Why?
| | Genetic Testing | 1 | 2008 | 425 | 0.250 |
Why?
| | Chloride Channel Agonists | 2 | 2021 | 73 | 0.250 |
Why?
| | Sinusitis | 3 | 2020 | 204 | 0.250 |
Why?
| | Aerosols | 2 | 2005 | 169 | 0.250 |
Why?
| | Water | 1 | 2008 | 441 | 0.240 |
Why?
| | Positive-Pressure Respiration | 1 | 2005 | 75 | 0.240 |
Why?
| | Estradiol | 1 | 2008 | 495 | 0.240 |
Why?
| | Anti-Bacterial Agents | 6 | 2014 | 1719 | 0.240 |
Why?
| | Proteins | 3 | 2012 | 948 | 0.240 |
Why?
| | Respiratory Function Tests | 6 | 2021 | 594 | 0.240 |
Why?
| | Antibodies, Monoclonal | 1 | 2012 | 1360 | 0.240 |
Why?
| | Homeostasis | 1 | 2008 | 604 | 0.240 |
Why?
| | Pyrrolidines | 2 | 2022 | 65 | 0.230 |
Why?
| | Curcumin | 1 | 2004 | 31 | 0.220 |
Why?
| | Lectins | 1 | 2024 | 46 | 0.220 |
Why?
| | Flavonoids | 1 | 2004 | 79 | 0.220 |
Why?
| | GPI-Linked Proteins | 1 | 2024 | 67 | 0.220 |
Why?
| | Mucin 5AC | 1 | 2024 | 69 | 0.220 |
Why?
| | Mucus | 1 | 2024 | 74 | 0.220 |
Why?
| | Plicamycin | 1 | 2003 | 3 | 0.210 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2017 | 1969 | 0.210 |
Why?
| | Genetic Vectors | 5 | 2005 | 315 | 0.210 |
Why?
| | Membrane Proteins | 2 | 2006 | 1108 | 0.210 |
Why?
| | Female | 39 | 2020 | 68561 | 0.210 |
Why?
| | Immunity, Innate | 1 | 2009 | 806 | 0.210 |
Why?
| | Amniotic Fluid | 1 | 2003 | 79 | 0.200 |
Why?
| | Male | 37 | 2020 | 63544 | 0.200 |
Why?
| | Forced Expiratory Volume | 6 | 2018 | 508 | 0.200 |
Why?
| | Signal Transduction | 4 | 2022 | 4863 | 0.200 |
Why?
| | Cell Cycle Proteins | 1 | 2006 | 577 | 0.200 |
Why?
| | Receptors, Prostaglandin E, EP2 Subtype | 1 | 2022 | 6 | 0.200 |
Why?
| | Peptides, Cyclic | 1 | 2004 | 258 | 0.190 |
Why?
| | Heterozygote | 2 | 2021 | 268 | 0.190 |
Why?
| | Prostaglandins | 1 | 2022 | 85 | 0.190 |
Why?
| | Nanoparticles | 3 | 2011 | 358 | 0.190 |
Why?
| | Animals | 19 | 2022 | 34733 | 0.190 |
Why?
| | Biological Transport | 3 | 2008 | 394 | 0.190 |
Why?
| | Pyrazoles | 2 | 2022 | 403 | 0.190 |
Why?
| | Child | 26 | 2024 | 20963 | 0.190 |
Why?
| | Pyridines | 2 | 2022 | 472 | 0.180 |
Why?
| | Oxadiazoles | 2 | 2014 | 35 | 0.180 |
Why?
| | Epithelial Sodium Channels | 1 | 2021 | 18 | 0.180 |
Why?
| | Aminopyridines | 2 | 2021 | 96 | 0.180 |
Why?
| | Quinolines | 1 | 2021 | 149 | 0.170 |
Why?
| | Tobramycin | 4 | 2014 | 52 | 0.170 |
Why?
| | Protein Structure, Tertiary | 2 | 2014 | 833 | 0.170 |
Why?
| | Antibodies, Viral | 2 | 2003 | 607 | 0.170 |
Why?
| | Molecular Chaperones | 3 | 2008 | 170 | 0.160 |
Why?
| | Protein Transport | 3 | 2014 | 424 | 0.160 |
Why?
| | Mice | 10 | 2022 | 16585 | 0.160 |
Why?
| | Paranasal Sinuses | 1 | 2020 | 72 | 0.160 |
Why?
| | Ergocalciferols | 2 | 2010 | 12 | 0.160 |
Why?
| | Ataxia Telangiectasia | 2 | 2010 | 17 | 0.160 |
Why?
| | Double-Blind Method | 6 | 2017 | 1871 | 0.160 |
Why?
| | Pulmonary Medicine | 2 | 2010 | 79 | 0.160 |
Why?
| | Cyclic AMP | 3 | 2008 | 231 | 0.160 |
Why?
| | Genotype | 6 | 2021 | 1836 | 0.160 |
Why?
| | Immunoglobulin G | 1 | 2003 | 842 | 0.150 |
Why?
| | Administration, Intranasal | 4 | 2007 | 86 | 0.150 |
Why?
| | Asthma | 2 | 2024 | 2257 | 0.150 |
Why?
| | Subcellular Fractions | 2 | 2008 | 80 | 0.150 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2020 | 199 | 0.150 |
Why?
| | Sweat | 4 | 2016 | 46 | 0.150 |
Why?
| | Administration, Inhalation | 8 | 2007 | 676 | 0.150 |
Why?
| | Vitamins | 2 | 2010 | 172 | 0.150 |
Why?
| | Cell Membrane | 2 | 2014 | 728 | 0.140 |
Why?
| | Biomarkers | 4 | 2017 | 3893 | 0.140 |
Why?
| | Membrane Transport Modulators | 1 | 2017 | 6 | 0.140 |
Why?
| | Respiratory Tract Infections | 3 | 2008 | 373 | 0.140 |
Why?
| | Maryland | 1 | 2017 | 43 | 0.140 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2017 | 29 | 0.140 |
Why?
| | Vitamin D Deficiency | 2 | 2010 | 179 | 0.140 |
Why?
| | Lung Diseases | 1 | 2003 | 757 | 0.140 |
Why?
| | Rifampin | 1 | 2017 | 84 | 0.130 |
Why?
| | Mice, Knockout | 3 | 2009 | 2778 | 0.130 |
Why?
| | Leukocyte Count | 1 | 2017 | 330 | 0.130 |
Why?
| | Adenosine Triphosphate | 2 | 2008 | 474 | 0.130 |
Why?
| | DNA-Binding Proteins | 1 | 2003 | 1423 | 0.130 |
Why?
| | Computational Biology | 2 | 2012 | 588 | 0.120 |
Why?
| | Drug Combinations | 3 | 2022 | 327 | 0.120 |
Why?
| | Transcription Factors | 1 | 2003 | 1636 | 0.120 |
Why?
| | Young Adult | 9 | 2020 | 12363 | 0.120 |
Why?
| | Gene Transfer Techniques | 3 | 2005 | 160 | 0.120 |
Why?
| | Child, Preschool | 11 | 2021 | 10565 | 0.120 |
Why?
| | Cell Line, Transformed | 2 | 2006 | 140 | 0.110 |
Why?
| | Drug Design | 2 | 2007 | 157 | 0.110 |
Why?
| | Sodium Chloride | 2 | 2005 | 141 | 0.110 |
Why?
| | Ubiquitination | 1 | 2014 | 96 | 0.110 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 2 | 2016 | 11 | 0.110 |
Why?
| | Exocrine Pancreatic Insufficiency | 2 | 2016 | 20 | 0.110 |
Why?
| | Amiloride | 2 | 2004 | 24 | 0.110 |
Why?
| | Protein Stability | 1 | 2014 | 160 | 0.110 |
Why?
| | Sleep | 1 | 2019 | 657 | 0.110 |
Why?
| | Cells, Cultured | 4 | 2021 | 4058 | 0.110 |
Why?
| | Proteolysis | 1 | 2014 | 162 | 0.110 |
Why?
| | Isoproterenol | 2 | 2004 | 111 | 0.110 |
Why?
| | Mass Spectrometry | 2 | 2014 | 659 | 0.110 |
Why?
| | Pediatrics | 3 | 2010 | 1071 | 0.100 |
Why?
| | Promoter Regions, Genetic | 3 | 2009 | 1195 | 0.100 |
Why?
| | Neutrophils | 2 | 2017 | 1205 | 0.100 |
Why?
| | Phenotype | 6 | 2016 | 3063 | 0.100 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 3 | 2009 | 96 | 0.100 |
Why?
| | RNA, Messenger | 4 | 2008 | 2705 | 0.100 |
Why?
| | Colforsin | 2 | 2021 | 51 | 0.100 |
Why?
| | HEK293 Cells | 1 | 2014 | 673 | 0.100 |
Why?
| | Enzyme Inhibitors | 2 | 2006 | 828 | 0.090 |
Why?
| | Expectorants | 1 | 2011 | 24 | 0.090 |
Why?
| | Down-Regulation | 3 | 2021 | 637 | 0.090 |
Why?
| | Staining and Labeling | 1 | 2012 | 142 | 0.090 |
Why?
| | Age Factors | 2 | 2017 | 3145 | 0.090 |
Why?
| | Protein Conformation | 1 | 2014 | 852 | 0.090 |
Why?
| | Mice, Inbred C57BL | 3 | 2013 | 5279 | 0.090 |
Why?
| | Research Personnel | 2 | 2010 | 163 | 0.090 |
Why?
| | Transduction, Genetic | 1 | 2011 | 128 | 0.090 |
Why?
| | Acetylcysteine | 1 | 2011 | 148 | 0.090 |
Why?
| | Vital Capacity | 1 | 2011 | 284 | 0.090 |
Why?
| | Endopeptidases | 1 | 2010 | 82 | 0.090 |
Why?
| | Cervix Mucus | 1 | 2009 | 1 | 0.080 |
Why?
| | Anhydrides | 1 | 2009 | 18 | 0.080 |
Why?
| | Microbiota | 1 | 2017 | 727 | 0.080 |
Why?
| | Rats | 4 | 2009 | 5244 | 0.080 |
Why?
| | Homozygote | 1 | 2010 | 192 | 0.080 |
Why?
| | Membrane Microdomains | 1 | 2009 | 32 | 0.080 |
Why?
| | Posterior Horn Cells | 1 | 2009 | 5 | 0.080 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2009 | 102 | 0.080 |
Why?
| | Synaptosomes | 1 | 2009 | 26 | 0.080 |
Why?
| | Models, Biological | 2 | 2007 | 1707 | 0.080 |
Why?
| | Models, Molecular | 1 | 2014 | 1480 | 0.080 |
Why?
| | Spiperone | 1 | 2008 | 1 | 0.080 |
Why?
| | Endoscopy | 1 | 2011 | 268 | 0.080 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 308 | 0.080 |
Why?
| | Drug Carriers | 1 | 2009 | 115 | 0.080 |
Why?
| | Nutrition Assessment | 1 | 2009 | 86 | 0.080 |
Why?
| | Ribosomes | 1 | 2010 | 162 | 0.080 |
Why?
| | Electric Conductivity | 1 | 2008 | 94 | 0.080 |
Why?
| | Respiratory System Agents | 1 | 2008 | 22 | 0.080 |
Why?
| | Administration, Topical | 1 | 2008 | 148 | 0.070 |
Why?
| | Polyethylene Glycols | 2 | 2011 | 598 | 0.070 |
Why?
| | Malnutrition | 1 | 2009 | 79 | 0.070 |
Why?
| | Biopsy | 1 | 2012 | 1098 | 0.070 |
Why?
| | Codon, Terminator | 2 | 2007 | 21 | 0.070 |
Why?
| | Tissue Distribution | 2 | 2005 | 296 | 0.070 |
Why?
| | Fibrous Dysplasia, Polyostotic | 1 | 2007 | 7 | 0.070 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 1 | 2007 | 8 | 0.070 |
Why?
| | Blotting, Western | 2 | 2007 | 1189 | 0.070 |
Why?
| | Statistics, Nonparametric | 2 | 2005 | 426 | 0.070 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2075 | 0.070 |
Why?
| | Adenoviridae | 2 | 2005 | 195 | 0.070 |
Why?
| | Cytosol | 1 | 2008 | 212 | 0.070 |
Why?
| | Treatment Outcome | 9 | 2018 | 10299 | 0.070 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2007 | 132 | 0.070 |
Why?
| | Aminoglycosides | 1 | 2007 | 22 | 0.070 |
Why?
| | Ibuprofen | 1 | 2007 | 79 | 0.070 |
Why?
| | Technology, Pharmaceutical | 1 | 2007 | 18 | 0.070 |
Why?
| | Metabolic Clearance Rate | 1 | 2007 | 107 | 0.070 |
Why?
| | Mannose-Binding Lectin | 1 | 2006 | 22 | 0.070 |
Why?
| | Socioeconomic Factors | 1 | 2011 | 1212 | 0.070 |
Why?
| | Cyclooxygenase 2 | 1 | 2007 | 172 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2007 | 149 | 0.070 |
Why?
| | HSP40 Heat-Shock Proteins | 1 | 2006 | 23 | 0.070 |
Why?
| | Nutritional Status | 1 | 2009 | 327 | 0.070 |
Why?
| | Airway Obstruction | 1 | 2008 | 170 | 0.070 |
Why?
| | Valosin Containing Protein | 1 | 2006 | 6 | 0.070 |
Why?
| | Polysaccharide-Lyases | 1 | 2006 | 11 | 0.070 |
Why?
| | DNA Primers | 1 | 2007 | 523 | 0.070 |
Why?
| | Tunicamycin | 1 | 2006 | 11 | 0.070 |
Why?
| | Proteasome Inhibitors | 1 | 2006 | 44 | 0.060 |
Why?
| | Chondroitin Sulfates | 1 | 2006 | 34 | 0.060 |
Why?
| | CHO Cells | 1 | 2006 | 146 | 0.060 |
Why?
| | DNA, Viral | 2 | 2005 | 381 | 0.060 |
Why?
| | Technetium Tc 99m Pentetate | 1 | 2005 | 7 | 0.060 |
Why?
| | Gamma Cameras | 1 | 2005 | 7 | 0.060 |
Why?
| | Luciferases | 2 | 2003 | 148 | 0.060 |
Why?
| | Cricetinae | 1 | 2006 | 275 | 0.060 |
Why?
| | Spinal Cord Injuries | 1 | 2009 | 190 | 0.060 |
Why?
| | Radionuclide Imaging | 1 | 2005 | 127 | 0.060 |
Why?
| | Glycosylation | 1 | 2006 | 144 | 0.060 |
Why?
| | Nitric Oxide Synthase | 1 | 2006 | 240 | 0.060 |
Why?
| | Glutamine | 1 | 2006 | 94 | 0.060 |
Why?
| | Purinergic P2 Receptor Agonists | 1 | 2005 | 4 | 0.060 |
Why?
| | Precision Medicine | 1 | 2009 | 385 | 0.060 |
Why?
| | Deoxycytosine Nucleotides | 1 | 2005 | 11 | 0.060 |
Why?
| | Adenosine Triphosphatases | 1 | 2006 | 164 | 0.060 |
Why?
| | Uridine | 1 | 2005 | 29 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 962 | 0.060 |
Why?
| | Nerve Tissue Proteins | 1 | 2009 | 568 | 0.060 |
Why?
| | Chronic Disease | 2 | 2008 | 1721 | 0.060 |
Why?
| | Radiopharmaceuticals | 1 | 2005 | 167 | 0.060 |
Why?
| | Acidosis | 1 | 2006 | 90 | 0.060 |
Why?
| | Polymers | 1 | 2009 | 475 | 0.060 |
Why?
| | Gene Expression Profiling | 3 | 2006 | 1696 | 0.060 |
Why?
| | DNA | 1 | 2011 | 1406 | 0.060 |
Why?
| | Particle Size | 1 | 2005 | 348 | 0.060 |
Why?
| | Nasal Polyps | 1 | 2004 | 58 | 0.060 |
Why?
| | Dietary Supplements | 1 | 2008 | 534 | 0.050 |
Why?
| | Inhalation Exposure | 1 | 2004 | 109 | 0.050 |
Why?
| | Bronchial Provocation Tests | 1 | 2003 | 50 | 0.050 |
Why?
| | Base Sequence | 1 | 2007 | 2161 | 0.050 |
Why?
| | Drug Administration Schedule | 4 | 2010 | 763 | 0.050 |
Why?
| | Transfection | 1 | 2006 | 904 | 0.050 |
Why?
| | Sp3 Transcription Factor | 1 | 2003 | 6 | 0.050 |
Why?
| | Biomedical Research | 1 | 2010 | 656 | 0.050 |
Why?
| | Recombinant Fusion Proteins | 2 | 2003 | 640 | 0.050 |
Why?
| | Heat-Shock Proteins | 1 | 2004 | 128 | 0.050 |
Why?
| | Diuretics | 1 | 2003 | 74 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2004 | 275 | 0.050 |
Why?
| | Protein Denaturation | 1 | 2003 | 73 | 0.050 |
Why?
| | RNA Interference | 1 | 2005 | 448 | 0.050 |
Why?
| | Xanthines | 1 | 2002 | 18 | 0.050 |
Why?
| | Isoflavones | 1 | 2002 | 25 | 0.050 |
Why?
| | Clinical Protocols | 1 | 2004 | 259 | 0.050 |
Why?
| | Sex Factors | 1 | 2008 | 1952 | 0.050 |
Why?
| | 5' Flanking Region | 1 | 2002 | 9 | 0.050 |
Why?
| | Biological Transport, Active | 1 | 2002 | 72 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 2 | 2008 | 2272 | 0.050 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2002 | 85 | 0.050 |
Why?
| | Disease Progression | 3 | 2017 | 2612 | 0.050 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2002 | 150 | 0.050 |
Why?
| | Carrier State | 1 | 2002 | 61 | 0.050 |
Why?
| | Aging | 2 | 2003 | 1769 | 0.050 |
Why?
| | Dimethyl Sulfoxide | 1 | 2022 | 41 | 0.050 |
Why?
| | Clinical Trials as Topic | 2 | 2004 | 1008 | 0.050 |
Why?
| | 1-Methyl-3-isobutylxanthine | 1 | 2021 | 24 | 0.050 |
Why?
| | Anesthesiologists | 1 | 2022 | 12 | 0.050 |
Why?
| | Forecasting | 1 | 2003 | 364 | 0.050 |
Why?
| | Bronchodilator Agents | 1 | 2003 | 253 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2003 | 369 | 0.050 |
Why?
| | Point Mutation | 1 | 2002 | 227 | 0.050 |
Why?
| | Interferon-gamma | 1 | 2005 | 765 | 0.050 |
Why?
| | Patient Acceptance of Health Care | 1 | 2008 | 776 | 0.050 |
Why?
| | NIH 3T3 Cells | 1 | 2021 | 142 | 0.050 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2006 | 1208 | 0.050 |
Why?
| | Electrophysiology | 1 | 2021 | 205 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2004 | 1024 | 0.050 |
Why?
| | Genetic Variation | 1 | 2006 | 936 | 0.050 |
Why?
| | Infant | 4 | 2020 | 9097 | 0.050 |
Why?
| | Up-Regulation | 1 | 2004 | 850 | 0.050 |
Why?
| | Nitric Oxide | 1 | 2006 | 894 | 0.050 |
Why?
| | Occupational Exposure | 1 | 2004 | 312 | 0.050 |
Why?
| | Codon, Nonsense | 2 | 2014 | 40 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2024 | 643 | 0.050 |
Why?
| | Anti-Infective Agents | 1 | 2003 | 249 | 0.040 |
Why?
| | Middle Aged | 8 | 2020 | 31103 | 0.040 |
Why?
| | Respiration | 1 | 2021 | 191 | 0.040 |
Why?
| | Nasal Surgical Procedures | 1 | 2020 | 6 | 0.040 |
Why?
| | Drug Monitoring | 2 | 2017 | 193 | 0.040 |
Why?
| | Viscosity | 2 | 2011 | 90 | 0.040 |
Why?
| | Cell Survival | 1 | 2003 | 1083 | 0.040 |
Why?
| | Animals, Newborn | 1 | 2002 | 819 | 0.040 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1409 | 0.040 |
Why?
| | Patient Care Team | 1 | 2004 | 607 | 0.040 |
Why?
| | Cytokines | 2 | 2024 | 2008 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2017 | 644 | 0.040 |
Why?
| | Albuterol | 1 | 2019 | 106 | 0.040 |
Why?
| | Spirometry | 1 | 2019 | 251 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1700 | 0.040 |
Why?
| | Haplotypes | 1 | 2020 | 476 | 0.040 |
Why?
| | Biological Products | 1 | 2021 | 202 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2670 | 0.040 |
Why?
| | Retrospective Studies | 5 | 2020 | 14669 | 0.040 |
Why?
| | Temperature | 1 | 2021 | 634 | 0.040 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2017 | 5 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2019 | 524 | 0.030 |
Why?
| | Bacteria | 1 | 2003 | 813 | 0.030 |
Why?
| | Biological Availability | 1 | 2017 | 129 | 0.030 |
Why?
| | Biphenyl Compounds | 1 | 2017 | 55 | 0.030 |
Why?
| | Seasons | 2 | 2010 | 508 | 0.030 |
Why?
| | Fellowships and Scholarships | 2 | 2010 | 271 | 0.030 |
Why?
| | DNA, Bacterial | 1 | 2017 | 326 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2003 | 1858 | 0.030 |
Why?
| | Drug Interactions | 1 | 2017 | 371 | 0.030 |
Why?
| | Pharmacogenetics | 1 | 2017 | 170 | 0.030 |
Why?
| | China | 1 | 2016 | 187 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2016 | 137 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 992 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2017 | 3363 | 0.030 |
Why?
| | Exons | 1 | 2016 | 330 | 0.030 |
Why?
| | Bronchiectasis | 1 | 2016 | 113 | 0.030 |
Why?
| | Colony Count, Microbial | 2 | 2005 | 117 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2005 | 2039 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1507 | 0.030 |
Why?
| | Time Factors | 3 | 2010 | 6593 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2007 | 1047 | 0.030 |
Why?
| | Genes, Reporter | 2 | 2005 | 269 | 0.030 |
Why?
| | Prevalence | 2 | 2010 | 2557 | 0.020 |
Why?
| | Polylysine | 1 | 2011 | 17 | 0.020 |
Why?
| | Biopolymers | 1 | 2011 | 32 | 0.020 |
Why?
| | Diffusion | 1 | 2011 | 118 | 0.020 |
Why?
| | Mucins | 1 | 2011 | 71 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2010 | 4939 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 2 | 2009 | 2314 | 0.020 |
Why?
| | Pregnancy | 1 | 2003 | 6273 | 0.020 |
Why?
| | Plasmids | 1 | 2011 | 359 | 0.020 |
Why?
| | CD4-CD8 Ratio | 1 | 2010 | 21 | 0.020 |
Why?
| | 25-Hydroxyvitamin D 2 | 1 | 2010 | 7 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 2539 | 0.020 |
Why?
| | alpha-Fetoproteins | 1 | 2010 | 39 | 0.020 |
Why?
| | Calcifediol | 1 | 2010 | 33 | 0.020 |
Why?
| | Accreditation | 1 | 2010 | 81 | 0.020 |
Why?
| | Cross-Sectional Studies | 2 | 2011 | 5050 | 0.020 |
Why?
| | Societies, Scientific | 1 | 2009 | 48 | 0.020 |
Why?
| | Immunoassay | 1 | 2010 | 104 | 0.020 |
Why?
| | Indicator Dilution Techniques | 1 | 2009 | 11 | 0.020 |
Why?
| | Adhesiveness | 1 | 2009 | 19 | 0.020 |
Why?
| | Mice, Inbred CFTR | 1 | 2008 | 5 | 0.020 |
Why?
| | Cohort Studies | 2 | 2011 | 5410 | 0.020 |
Why?
| | Type C Phospholipases | 1 | 2008 | 72 | 0.020 |
Why?
| | Baltimore | 1 | 2008 | 46 | 0.020 |
Why?
| | Biological Assay | 1 | 2008 | 117 | 0.020 |
Why?
| | Small Molecule Libraries | 1 | 2008 | 85 | 0.020 |
Why?
| | Drug Discovery | 1 | 2008 | 131 | 0.020 |
Why?
| | Cell Polarity | 1 | 2008 | 139 | 0.020 |
Why?
| | Hospitals, University | 1 | 2008 | 177 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2010 | 394 | 0.020 |
Why?
| | Quality of Life | 1 | 2019 | 2712 | 0.020 |
Why?
| | Career Choice | 1 | 2009 | 211 | 0.020 |
Why?
| | Models, Animal | 1 | 2009 | 370 | 0.020 |
Why?
| | Placebos | 1 | 2007 | 203 | 0.020 |
Why?
| | Solutions | 1 | 2007 | 147 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2009 | 379 | 0.020 |
Why?
| | Gentamicins | 1 | 2007 | 51 | 0.020 |
Why?
| | Sulfur Radioisotopes | 1 | 2006 | 16 | 0.020 |
Why?
| | Silver Staining | 1 | 2006 | 17 | 0.020 |
Why?
| | Prospective Studies | 1 | 2018 | 7130 | 0.020 |
Why?
| | Dual Oxidases | 1 | 2006 | 2 | 0.020 |
Why?
| | Flavoproteins | 1 | 2006 | 8 | 0.020 |
Why?
| | Salivary Proteins and Peptides | 1 | 2006 | 10 | 0.020 |
Why?
| | Comorbidity | 1 | 2011 | 1545 | 0.020 |
Why?
| | Peptide Mapping | 1 | 2006 | 62 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2014 | 787 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2008 | 259 | 0.020 |
Why?
| | Energy Intake | 1 | 2009 | 460 | 0.020 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2006 | 136 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2008 | 564 | 0.020 |
Why?
| | NADPH Oxidases | 1 | 2006 | 108 | 0.020 |
Why?
| | Cell Membrane Permeability | 1 | 2006 | 82 | 0.020 |
Why?
| | Blotting, Southern | 1 | 2005 | 69 | 0.020 |
Why?
| | Methionine | 1 | 2006 | 159 | 0.020 |
Why?
| | Serum | 1 | 2006 | 57 | 0.020 |
Why?
| | Education, Medical, Graduate | 1 | 2010 | 438 | 0.020 |
Why?
| | Societies, Medical | 1 | 2009 | 763 | 0.020 |
Why?
| | Receptors, Purinergic P2Y2 | 1 | 2005 | 6 | 0.020 |
Why?
| | Helper Viruses | 1 | 2005 | 2 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2008 | 421 | 0.020 |
Why?
| | Burkholderia | 1 | 2005 | 13 | 0.020 |
Why?
| | Severity of Illness Index | 2 | 2004 | 2783 | 0.020 |
Why?
| | Pancreatic Elastase | 1 | 2005 | 60 | 0.020 |
Why?
| | Nasal Cavity | 1 | 2005 | 53 | 0.010 |
Why?
| | Hemoptysis | 1 | 2005 | 36 | 0.010 |
Why?
| | Peroxidase | 1 | 2005 | 183 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2006 | 544 | 0.010 |
Why?
| | Kaplan-Meier Estimate | 1 | 2006 | 863 | 0.010 |
Why?
| | Quality of Health Care | 1 | 2009 | 616 | 0.010 |
Why?
| | Reference Values | 1 | 2006 | 792 | 0.010 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2004 | 44 | 0.010 |
Why?
| | Syndrome | 1 | 2004 | 343 | 0.010 |
Why?
| | Siblings | 1 | 2004 | 220 | 0.010 |
Why?
| | Antibodies | 1 | 2006 | 392 | 0.010 |
Why?
| | DNA, Recombinant | 1 | 2003 | 46 | 0.010 |
Why?
| | Treatment Failure | 1 | 2004 | 347 | 0.010 |
Why?
| | Heating | 1 | 2003 | 20 | 0.010 |
Why?
| | Saline Solution, Hypertonic | 1 | 2003 | 40 | 0.010 |
Why?
| | Survival Analysis | 1 | 2006 | 1297 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2006 | 1227 | 0.010 |
Why?
| | Virus Shedding | 1 | 2003 | 44 | 0.010 |
Why?
| | Survivors | 1 | 2006 | 458 | 0.010 |
Why?
| | Dyspnea | 1 | 2005 | 239 | 0.010 |
Why?
| | Hearing Disorders | 1 | 2002 | 9 | 0.010 |
Why?
| | Logistic Models | 1 | 2008 | 1980 | 0.010 |
Why?
| | Probability | 1 | 2004 | 315 | 0.010 |
Why?
| | Audiometry | 1 | 2002 | 27 | 0.010 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2002 | 21 | 0.010 |
Why?
| | Oropharynx | 1 | 2002 | 42 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2003 | 319 | 0.010 |
Why?
| | Bronchoscopy | 1 | 2004 | 220 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 2003 | 399 | 0.010 |
Why?
| | Viremia | 1 | 2003 | 133 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2009 | 1222 | 0.010 |
Why?
| | United States | 2 | 2010 | 14078 | 0.010 |
Why?
| | Embryonic and Fetal Development | 1 | 2002 | 95 | 0.010 |
Why?
| | Genetic Linkage | 1 | 2002 | 298 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2004 | 773 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2005 | 1306 | 0.010 |
Why?
| | Interleukins | 1 | 2003 | 245 | 0.010 |
Why?
| | Gene Rearrangement | 1 | 2002 | 151 | 0.010 |
Why?
| | Recurrence | 1 | 2004 | 1016 | 0.010 |
Why?
| | Prognosis | 1 | 2010 | 3801 | 0.010 |
Why?
| | Pedigree | 1 | 2002 | 491 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 2002 | 391 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2002 | 517 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 828 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2005 | 715 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2004 | 1288 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1477 | 0.010 |
Why?
| | Safety | 1 | 2002 | 328 | 0.010 |
Why?
| | Creatinine | 1 | 2002 | 485 | 0.010 |
Why?
| | Body Mass Index | 1 | 2009 | 2246 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1849 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2002 | 929 | 0.010 |
Why?
| | Kinetics | 1 | 2004 | 1620 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2004 | 876 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2008 | 3054 | 0.010 |
Why?
| | Apoptosis | 1 | 2009 | 2485 | 0.010 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2008 | 1291 | 0.010 |
Why?
| | Kidney Diseases | 1 | 2002 | 367 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2008 | 4016 | 0.010 |
Why?
| | Fetus | 1 | 2002 | 764 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2010 | 5396 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2008 | 5752 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 2002 | 895 | 0.010 |
Why?
| | Hospitalization | 1 | 2005 | 2091 | 0.010 |
Why?
| | Risk Assessment | 1 | 2004 | 3297 | 0.010 |
Why?
| | Risk Factors | 1 | 2008 | 9832 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2002 | 2353 | 0.010 |
Why?
|
|
Zeitlin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|